A hopeful therapeutic method that has exposed acceptable efficacy in tumors is the use of the checkpoint inhibitors, which target the PD-1/PD-L1 or CTLA-4 pathways (Fig. 5) [132, 133]; in this case, checkpoint blockade is ameliorated following improving the preparation of tumor-specific T cells and may rationally be composed with the adoptive transmission of CAR T cells, while the risk of toxicity may be improved in normal calls. This evidence concerns the gene CD274 and neoplasm.